BiotechTube
Home/Cellbricks Therapeutics/Michael Kring
MK

Michael Kring

Chief Financial Officer

Cellbricks Therapeutics

Therapeutic Areas

Tissue DysfunctionOrgan FailureSoft Tissue Defects

Cellbricks Therapeutics Pipeline

DrugIndicationPhase
Undisclosed Tissue Therapeutic(s)Soft tissue defects and organ dysfunctionPre-clinical